DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype

Haematologica

Volumn 100, Issue 11, 2015, Pages e438-e442

  Nangalia, Jyoti ^a,b,c   Nice, Francesca L ^a   Wedge, David C ^c   Godfrey, Anna L ^a,b   Grinfeld, Jacob ^a,b,c   Thakker, Clare ^a   Massie, Charlie E ^a   Baxter, Joanna ^b,d   Sewell, David ^b,d   Silber, Yvonne ^a   Campbell, Peter J ^a,b,c   Green, Anthony R ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

DNMT3A mutation; Mutation order; Myeloproliferative neoplasms

Indexed keywords

ALPHA INTERFERON; DNA METHYLTRANSFERASE 3A; HYDROXYUREA; JANUS KINASE 2; PIPOBROMAN; DNA (CYTOSINE 5) METHYLTRANSFERASE; TUMOR PROTEIN;

ARTICLE; GENE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; MPL GENE; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PHENOTYPE; POLYCYTHEMIA; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTHEMIA; X CHROMOSOME; ENZYMOLOGY; FEMALE; GENETICS; HEMATOLOGIC DISEASE; MALE; MUTATION; MYELOPROLIFERATIVE DISORDER;

DNA (CYTOSINE-5-)-METHYLTRANSFERASE; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MUTATION; MYELOPROLIFERATIVE DISORDERS; NEOPLASM PROTEINS;

EID: 84946237823     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.129510     Document Type: Article

References (15)

1. Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clini cal correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220–2228.
2. Ortmann CA, Kent DG, Nangalia J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372(7):601–612.
3. Stegelmann F, Bullinger L, Schlenk RF, et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia. 2011;25(7):1217–1219.
4. Abdel-Wahab O, Pardanani A, Rampal R, Lasho TL, Levine RL, Tefferi A. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia. 2011;25(7):1219–1220.
5. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–2405.
6. Rao N, Butcher CM, Lewis ID, et al. Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient. Br J Haematol. 2012;156(2):268–270.
7. Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506(7488):328–333.
8. Fried I, Bodner C, Pichler MM, et al. Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia. Haematologica. 2012;97(2):246–250.
9. Kralovics R, Teo S-S, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108(4):1377–1380.
10. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488–2498.
11. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477–2487.
12. Challen GA, Sun D, Jeong M, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2012;44(1):23–31.
13. Ko M, Bandukwala HS, An J, et al. Ten-eleven-translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci USA. 2011;108(35):14566–14571.
14. Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20(1):11–24.
15. Li J, Kent DG, Chen E, Green AR. Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis Model Mech. 2011;4(3):311–317.